Articles published by Deciphera Pharmaceuticals Inc.

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

Deciphera Announces the Opening of a New Office in Zug, Switzerland

November 17, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

November 12, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

October 18, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

September 17, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

February 14, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Deciphera Pharmaceuticals Inc.

Starting at $3.75/week.

Subscribe Today